研究确定拉贝普拉 (PPI) 和急性间歇性炎 (AIN) 之间的关系
Bite Bapurao1, Swanand Pathak1, Ranjit Sidram Ambad2
1Department of Pharmacology Jawaharlal Nehru Medical College, Wardha, Maharashtra, India.
Journal of pharmacy & bioallied sciences
|June 13, 2025
概括
质子抑制剂 (PPI) 在长时间使用时可能导致损伤. 将PPI与迪克洛菲纳克或奥洛辛结合使用可能会加快这种损伤,如功能测试的改变所示.
科学领域:
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药品安全 药品安全
背景情况:
- 质子抑制剂 (PPI),通常使用的胺衍生物,是口服的,并在酸性环境中激活,通过与H+/K+ ATPase酶结合来不可逆转地抑制酸分泌.
- 它们的基本性质需要肠道涂层来防止胃酸的降解.
研究的目的:
- 调查拉贝普拉 (一种PPI) 和急性间歇性炎 (AIN) 之间的关系.
- 评估PPI单疗法和与迪克洛菲纳克 (NSAID) 或奥洛辛 (抗菌剂) 联合治疗对功能测试的影响.
主要方法:
- 这项研究使用了欧梅普拉作为主要的PPI组,分为三个分组,每组6只大鼠.
- PPI和AIN之间的关系是通过单独使用PPI以及与迪克洛菲纳克和奥洛辛联合使用来评估的.
主要成果:
- 仅拉贝普拉 (20毫克/千克/天) 单独显著改变了血清肌素和血尿素值.
- 同时服用拉贝普拉 (20 mg/kg/day) 和狄克洛菲纳克显著影响了功能测试.
- 拉贝普拉 (20 mg/kg/day) 与奥夫洛克萨 (60 mg/kg/day) 结合使用,并没有显示血清肌和血尿素的统计学上显著变化.
结论:
- 长时间服用PPI可能导致功能测试失调,表明潜在的损伤.
- 同时使用PPI与奥洛素和迪克洛菲纳克似乎加快了损伤的过程,由改变的功能测试证明.
更多相关视频
相关概念视频
01:25Antihypertensive Drugs: Direct Renin Inhibitors
511
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
511
01:11Renal Failure: Dose Adjustments
69
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
69
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
410
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
410
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
154
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
154
01:21Drugs for Treatment of Constipation-Predominant IBS
146
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
146
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404